Focal Interest
Focal Interest
AI Summary of Peer-Reviewed Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Publishing process signals: MODERATE — reflects the venue and review process. — venue and review process.

Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2

A researcher in a white lab coat wearing blue gloves works at a laboratory bench with scientific equipment, a computer monitor, and various laboratory supplies and containers in a modern biomedical research facility.
Research area:OncologyDNA Repair MechanismsPARP inhibition in cancer therapy

What the study found

Resistance to neoadjuvant talazoparib in triple-negative breast cancer was linked to two different mechanisms: BRN2-induced activation of ATR/RAD51 and STAT3 pathways, and expansion of an HR repair proficient tumor subclone lacking Shieldin 2 expression.

Why the authors say this matters

The authors conclude that determining intrinsic and anticipating acquired resistance pathways in treatment-naïve tumors matters, and they support combining PARPi, or poly(ADP-ribose) polymerase inhibitors, with targeted agents to improve outcomes in the neoadjuvant setting.

What the researchers tested

The study examined resistance to neoadjuvant talazoparib in triple-negative breast cancer. It investigated BRN2-associated pathway changes and the behavior of a tumor subclone lacking Shieldin 2 expression during treatment.

What worked and what didn't

BRN2-driven resistance was associated with activation of ATR/RAD51 and STAT3 pathways and restoration of homologous recombination (HR) repair. This resistance could be reversed with ATR and STAT3 inhibitors, which resensitized cells to talazoparib. In another case, an HR repair proficient subclone lacking Shieldin 2 expanded during treatment and accounted for intrinsic resistance.

What to keep in mind

The abstract does not describe study size, patient numbers, or detailed methods. It also does not provide broader outcome data beyond the resistance mechanisms reported.

Key points

  • Talazoparib resistance in triple-negative breast cancer was linked to BRN2-induced ATR/RAD51 and STAT3 pathway activation.
  • BRN2-driven resistance was associated with restored homologous recombination repair.
  • ATR and STAT3 inhibitors reversed BRN2-driven resistance and resensitized cells to talazoparib.
  • An HR repair proficient subclone lacking Shieldin 2 expression expanded during treatment and was tied to intrinsic resistance.
  • The authors support combining PARP inhibitors with targeted agents in the neoadjuvant setting.

Disclosure

Research title:
Talazoparib resistance in triple-negative breast cancer linked to BRN2 and SHLD2
Authors:
Noor Mazin Abdulkareem, Yan Jiang, Y. Qi, Xuan Liu, Xiaomei Zhang, Shirong Cai, J Shao, Sabrina L. Jeter-Jones, Amanda L. Rinkenbaugh, Chun-Chun Cheng, Faiza Baameur Hancock, Jill L. Schwartz, Jennifer K. Litton, Jeffrey T. Chang, H Piwnica-Worms
Institutions:
The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center at Houston
Publication date:
2026-04-10
DOI:
10.1073/pnas.2513742123
OpenAlex record:
View
AI provenance: This post was generated by OpenAI. The original authors did not write or review this post.

More posts